Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. (NASDAQ: COSM) generates a steady flow of news across pharmaceuticals, nutraceuticals, healthcare services and digital assets, reflecting its description as a diversified, vertically integrated global healthcare group. News coverage often highlights developments in its proprietary brands, EU-based manufacturing operations, distribution activities, research and development programs, telehealth initiatives and financing arrangements.
Recent press releases have focused on record quarterly financial results, including revenue growth and margin expansion attributed to contract manufacturing at Cana Laboratories, UK distribution through Decahedron, the CosmoFarm distribution business, and global expansion of brands such as Sky Premium Life and C-Sept/C-Scrub. Coverage has also included manufacturing agreements, such as the PathMuscle production agreement through Cana Laboratories, which illustrates the company’s role as a pharmaceutical manufacturing partner.
Investors following COSM news will also see updates on Cosmos Health’s R&D pipeline, including programs like CCX0722 for obesity and weight management and other repurposed compounds targeting major disorders. News items describe how these efforts are supported by the Cloudscreen AI-enabled drug repurposing platform and by initiatives in nanotechnology to develop next-generation nutraceutical formulas.
Beyond core healthcare operations, Cosmos Health issues news about its digital asset strategy, including Ethereum purchases under a $300 million facility and a strategic partnership with Prime Ledger LLC to manage digital asset treasury operations and tokenize intellectual property. Regulatory and capital markets updates, such as Nasdaq listing compliance notices, financing transactions involving senior secured convertible notes, and shareholder meeting outcomes, also feature prominently.
For readers tracking COSM, this news stream provides insight into how the company is executing across manufacturing, distribution, R&D, telehealth and digital finance. Regular updates help contextualize financial performance, strategic partnerships and regulatory milestones that shape Cosmos Health’s trajectory.
Cosmos Health (NASDAQ:COSM) reported a record quarter with revenue north of $17 million and expanding gross profit margins, marking the company's highest revenue in history on December 19, 2025. Management highlights operational scale across pharmaceuticals, nutraceuticals and healthcare services, plus manufacturing compliant with European GMP and established distribution.
The company completed acquisitions of ZipDoctor and Cloudscreen, CEO Greg Siokas continued share purchases, and Cosmos disclosed a $500,000 Ethereum purchase, bringing total digital investments to over $2 million under a $300 million facility.
Cosmos Health (NASDAQ:COSM) announced a long-term strategic partnership with Prime Ledger to digitally transform its financial operations and tokenize intellectual property. The agreement centers on Prime Ledger assisting to manage Cosmos Health’s $300,000,000 treasury, implementing controls, protocols, and reporting for Digital Asset Treasury (DAT) management, and deploying a token issuance platform for high-value IP assets. The collaboration includes integration with Conduit Network to consolidate on-chain and off-chain data for financial reporting, compliance, and real-time analytics. The initial phase begins in Q4 2025 and will focus on strategy, regulatory mapping, and platform architecture.
Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas increased his stake during 2025, adding 3,398,055 shares year-to-date, including 301,101 shares bought between Nov 19–28, 2025. Following these purchases, his total ownership stands at 6,459,985 shares. The company noted record-breaking Q3 2025 results across revenue, gross profit, and gross margins but said its valuation remains under pressure. The release directs investors to Form 4 filings for transaction-level details such as ownership form, dates, amounts, and prices.
Cosmos Health (NASDAQ:COSM) reported record Q3 2025 results with revenue up 38% to $17.11M, gross profit up 116% to $2.60M, and a record gross margin of 15.21%. Adjusted EBITDA improved 74% to ($0.19M) and adjusted EPS narrowed to ($0.02) in Q3; nine-month adjusted EPS turned positive to $0.02. Cash rose sharply to $4.63M from $0.66M at June 30, 2025. The company secured a $300M digital financing facility and began Ethereum purchases, expanded U.S. operations for Sky Premium Life, and signed a contract manufacturing deal for MYCOFAGYL. Operating loss and GAAP net loss widened due to non-cash derivative and convertible-note charges.
Cosmos Health (NASDAQ:COSM) announced a new nanotechnology R&D program launched on October 31, 2025 to develop plant-based extract-loaded phytosomes for dietary supplements.
The program builds on the company’s CCX Hydrogel platform and aims to improve absorption, stability, and bioactivity of phytochemicals using a sustainable, solvent-free process suitable for nutraceutical formulation. Company leaders described the work as an effort to deliver next-generation, scientifically driven supplements with validated functional performance.
Cosmos Health (NASDAQ:COSM) announced on October 21, 2025 that it purchased an additional $200,000 of Ethereum (ETH), bringing its total ETH holdings to $2 million.
The acquisition was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify and strengthen its long‑term asset base through targeted digital asset investments.
Cosmos Health (NASDAQ:COSM) announced on October 16, 2025 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement. Nasdaq confirmed the company’s closing bid price was at or above $1.00 for 18 consecutive business days from September 22, 2025 to October 15, 2025. As a result, Nasdaq has closed the matter and the Company is now in compliance with the listing rule. The company said this compliance was achieved organically and attributed to execution of strategic initiatives and strengthening fundamentals, and reiterated focus on shareholder value and its digital asset strategy.
Cosmos Health (NASDAQ:COSM) announced on October 13, 2025 that it purchased an additional $300,000 of Ethereum (ETH), bringing its total ETH holdings to $1.8 million. The purchase was executed under the company’s existing $300 million digital assets facility, which the company says supports its strategy to diversify holdings via strategic digital asset investments. Management reiterated commitment to continue the acquisition program under the financing facility.
Cosmos Health (NASDAQ:COSM) announced on October 10, 2025 that it purchased an additional $500,000 of Ethereum (ETH), bringing its total ETH holdings to $1.5 million. The purchase was executed under the company’s existing $300 million digital assets facility as part of a balance-sheet diversification strategy and to explore blockchain-enabled healthcare solutions. Management reiterated intent to continue using the financing facility and described digital assets as both long-term investments and potential enablers of decentralized healthcare applications.
Cosmos Health (NASDAQ:COSM) announced that subsidiary SkyPharm S.A. signed an exclusive distribution agreement dated September 28, 2025 with Diyar United to market and sell Sky Premium Life® nutraceuticals in Kuwait. Diyar United will manage registration, promotion, logistics and distribution for formulations including collagen, hyaluronic acid, vitamins B/C/D3+K2, magnesium, zinc, turmeric, maca, rhodiola, multivitamins and hair/skin/nail blends. Cosmos secured an initial purchase order of over 65,000 units, with further orders expected as the sales pipeline develops. The PR cites Kuwait’s supplements market at $1.16B in 2024, projected to $1.68B by 2030 (CAGR ~6.3%).